Drug Type Autologous CAR-T |
Synonyms Anti-CD19/CD20 CAR-T cell therapy (Juventas Cell Therapy), CD19/CD20 CART cell therapy (Juventas Cell Therapy), CD19/CD20 chimeric antigen receptor Tcell therapy (Juventas Cell Therapy) + [2] |
Target |
Mechanism CD19 inhibitors(B-lymphocyte antigen CD19 inhibitors), CD20 inhibitors(B-lymphocyte antigen CD20 inhibitors), Gene transference |
Therapeutic Areas |
Inactive Indication- |
Originator Organization Juventas Cell Therapy Ltd.Startup |
Active Organization Juventas Cell Therapy Ltd.Startup |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
B-cell lymphoma refractory | Phase 2 | - | Juventas Cell Therapy Ltd.Startup | 31 Aug 2024 |
Pre B-cell acute lymphoblastic leukemia | Phase 2 | - | Juventas Cell Therapy Ltd.Startup | 31 Aug 2024 |
CD19-positive B-cell acute lymphoblastic leukemia | Phase 1 | CN | Juventas Cell Therapy Ltd.Startup | 26 Sep 2023 |
CD22 Positive B-cell Acute Lymphoblastic Leukemia | Phase 1 | CN | Juventas Cell Therapy Ltd.Startup | 26 Sep 2023 |
B-Cell Lymphoma | Phase 1 | CN | Juventas Cell Therapy Ltd.Startup | 30 Aug 2023 |